A multi-cancer early detection (MCED) test that screens for 50 different types of cancer is being marketed as a life-saving tool. The Galleri test, developed by Grail, claims to detect cancers at an early stage when symptoms are not yet apparent. However, experts have raised concerns about the test’s accuracy, cost, and potential benefits.
The Galleri test can identify over 50 types of cancer from a single blood draw, including lung, breast, colon, liver, and ovarian cancer. Critics argue that there isn’t enough evidence to prove that the test leads to lower death rates from cancer. Long-term randomized trials are needed to confirm the effectiveness of MCED tests like Galleri.
The cost of the test is $949, making it out of reach for most people. However, experts emphasize that the test should be used in addition to routine screening tests like colonoscopies and mammograms, rather than replacing them.
Ultimately, whether or not to get the multi-cancer early detection blood test depends on individual risk factors, including family history and disease risk tolerance. Experts recommend discussing the benefits and downsides with a healthcare provider and understanding that more research is needed to fully understand the test’s potential.
Key points:
* The Galleri test can identify over 50 types of cancer from a single blood draw
* Critics argue that there isn’t enough evidence to prove the test’s effectiveness in reducing death rates from cancer
* The cost of the test is $949, making it out of reach for most people
* Experts recommend using the test in addition to routine screening tests, rather than replacing them
* Individual risk factors, including family history and disease risk tolerance, should be taken into consideration when deciding whether or not to get the test.
Source: https://www.yahoo.com/lifestyle/this-blood-test-screens-for-50-different-types-of-cancer-is-it-worth-the-949-price-tag-221004571.html